Literature DB >> 16522999

Doxazosin gastrointestinal therapeutic system: a clinical perspective.

Samuel J Mann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16522999      PMCID： PMC8109464          DOI： 10.1111/j.1524-6175.2005.05363.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  12 in total

1.  Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.

Authors:  M Chung; V Vashi; J Puente; M Sweeney; P Meredith
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.

Authors:  M J Brown; J E Dickerson
Journal:  J Hypertens Suppl       Date:  1991-12

3.  The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.

Authors:  H R Black; J S Sollins; J L Garofalo
Journal:  Am J Hypertens       Date:  2000-05       Impact factor: 2.689

Review 4.  Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension.

Authors:  S Julius
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

5.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Authors:  George L Bakris; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Jackson T Wright; Rosemary Oakes; Mary Ann Lukas; Karen M Anderson; David S H Bell
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

Review 7.  Neurogenic essential hypertension revisited: the case for increased clinical and research attention.

Authors:  Samuel J Mann
Journal:  Am J Hypertens       Date:  2003-10       Impact factor: 2.689

Review 8.  Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension.

Authors:  Henry R Black
Journal:  J Cardiovasc Pharmacol       Date:  2003-06       Impact factor: 3.105

Review 9.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

10.  Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.

Authors:  D Levy; P Walmsley; M Levenstein
Journal:  Am Heart J       Date:  1996-05       Impact factor: 4.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.